In colorectal cancer and pancreatic neuroendocrine neoplasm, NAP1L1 was found to be a biomarker, involved in the pathogenesis of these two types of cancers (Schimmack et al., 2014; Zhai et al., 2018; Queiroz et al., 2020). Here, NAP1L1 is linked to pancreatic neuroendocrine neoplasm.